INSMED Inc (INSM): who owns it and who trades it
As of Nov 16, 2026, INSM insiders reported 152 open-market sales worth $148M and no purchases in the last 12 months, with 56% of the sale value made under pre-set 10b5-1 plans. The largest seller was Roger Adsett (Chief Operating Officer), with $48.3M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling INSMED
From the latest filingsOverall: more selling than buying. Insiders, famous investors and Congress mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns INSM
662 funds and institutions reported INSM shares worth $23.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 7.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 16.14M | 7.45% | $1.7B | +23% |
| BlackRock, Inc. | 15.81M | 7.29% | $1.7B | -5% |
| JPMorgan Chase & Co | 10.43M | 4.81% | $1.1B | – |
| Vanguard Portfolio Management LLC | 10.41M | 4.80% | $1.1B | +0% |
| Vanguard Capital Management LLC | 9.79M | 4.52% | $1B | +2% |
| Baker Bros. Advisors LP | 8.80M | 4.06% | $938M | +19% |
| Capital International Investors | 8.24M | 3.80% | $878M | +47% |
| Darwin Global Management, Ltd. | 6.43M | 2.97% | $674M | -62% |
| Ameriprise Financial Inc | 6.18M | 2.85% | $659M | +102% |
| Orbis Allan Gray Ltd | 6.08M | 2.80% | $648M | +224% |
| State Street Corp | 6.05M | 2.79% | $645M | +9% |
| D. E. Shaw & Co., Inc. | 5.88M | 2.71% | $627M | +4% |
| Artisan Partners Limited Partnership | 5.44M | 2.51% | $580M | -17% |
| Rtw Investments, LP | 4.84M | 2.23% | $516M | No change |
| Geode Capital Management, LLC | 4.22M | 1.95% | $449M | -5% |
| T. Rowe Price Associates | 3.41M | 1.57% | $363M | +10% |
| Norges Bank | 3.38M | 1.56% | $360M | – |
| Jupiter Topco LLC | 2.61M | 1.20% | $278M | – |
| UBS Group AG | 2.58M | 1.19% | $276M | +49% |
| Citadel Advisors LLC | 2.56M | 1.18% | $273M | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, INSM insiders reported $0 of open-market purchases and $148M of sales. 56% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | David R Brennan | Director | Sale | 25,000 | $124.00 | $3.1M | Form 4 |
| Aug 17, 2026 | Melvin Md Sharoky | Director | Sale | 5,000 | $127.53 | $638K | Form 4 |
| Aug 10, 2026 | Roger Adsett | Chief Operating Officer | Sale | 239,850 | $133.27 | $32M | Form 4 |
| Aug 6, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 8,895 | $127.00 | $1.1M | Form 4 |
| Aug 6, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 18,278 | $129.40 | $2.4M | Form 4 |
| Jul 23, 2026 | William Lewis | CEO | Sale plan | 4,828 | $105.62 | $510K | Form 4 |
| Jul 23, 2026 | William Lewis | CEO | Sale plan | 5,872 | $106.43 | $625K | Form 4 |
| Jul 9, 2026 | William Lewis | CEO | Sale plan | 2,335 | $117.62 | $275K | Form 4 |
| Jul 9, 2026 | William Lewis | CEO | Sale plan | 3,359 | $118.52 | $398K | Form 4 |
| Jul 9, 2026 | William Lewis | CEO | Sale plan | 5,005 | $116.55 | $583K | Form 4 |
| Jul 6, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 7,448 | $110.60 | $824K | Form 4 |
| Jul 6, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 4,854 | $109.02 | $529K | Form 4 |
| Jun 25, 2026 | William Lewis | CEO | Sale plan | 1,292 | $106.27 | $137K | Form 4 |
| Jun 25, 2026 | William Lewis | CEO | Sale plan | 2,456 | $105.27 | $259K | Form 4 |
| Jun 25, 2026 | William Lewis | CEO | Sale plan | 3,723 | $104.28 | $388K | Form 4 |
| Jun 25, 2026 | William Lewis | CEO | Sale plan | 1,836 | $103.10 | $189K | Form 4 |
| Jun 25, 2026 | William Lewis | CEO | Sale plan | 12,091 | $102.34 | $1.2M | Form 4 |
| Jun 22, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 1,806 | $95.82 | $173K | Form 4 |
| Jun 8, 2026 | William Lewis | CEO | Sale plan | 6,515 | $94.03 | $613K | Form 4 |
| Jun 5, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 1,858 | $103.78 | $193K | Form 4 |
| Jun 3, 2026 | Roger Adsett | Chief Operating Officer | Sale | 2,370 | $102.27 | $242K | Form 4 |
| Jun 3, 2026 | Sara Bonstein | CFO | Sale | 2,404 | $102.27 | $246K | Form 4 |
| Jun 3, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale | 2,159 | $102.27 | $221K | Form 4 |
| Jun 3, 2026 | William Lewis | CEO | Sale | 7,605 | $102.27 | $778K | Form 4 |
| Jun 3, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 2,566 | $102.27 | $262K | Form 4 |
| May 22, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 6,149 | $108.47 | $667K | Form 4 |
| May 18, 2026 | William Lewis | CEO | Sale plan | 7,975 | $106.97 | $853K | Form 4 |
| May 18, 2026 | William Lewis | CEO | Sale plan | 5,753 | $105.32 | $606K | Form 4 |
| May 18, 2026 | William Lewis | CEO | Sale plan | 11,836 | $106.39 | $1.3M | Form 4 |
| May 14, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 10,479 | $117.54 | $1.2M | Form 4 |
| May 13, 2026 | Sara Bonstein | CFO | Sale | 8,272 | $116.18 | $961K | Form 4 |
| May 13, 2026 | Roger Adsett | Chief Operating Officer | Sale | 5,837 | $116.18 | $678K | Form 4 |
| May 13, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 4,470 | $112.76 | $504K | Form 4 |
| May 13, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 3,384 | $116.18 | $393K | Form 4 |
| May 13, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale | 4,109 | $116.18 | $477K | Form 4 |
| May 13, 2026 | William Lewis | CEO | Sale | 13,283 | $116.18 | $1.5M | Form 4 |
| May 11, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 12,119 | $100.35 | $1.2M | Form 4 |
| May 11, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 830 | $101.18 | $84K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 433 | $134.18 | $58.1K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 381 | $139.60 | $53.2K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 5,318 | $137.01 | $729K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 2,721 | $137.86 | $375K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 1,247 | $139.09 | $173K | Form 4 |
| May 4, 2026 | William Lewis | CEO | Sale plan | 599 | $135.18 | $81K | Form 4 |
| Apr 16, 2026 | William Lewis | CEO | Sale plan | 2,246 | $142.99 | $321K | Form 4 |
| Apr 16, 2026 | William Lewis | CEO | Sale plan | 5,373 | $143.81 | $773K | Form 4 |
| Apr 16, 2026 | William Lewis | CEO | Sale plan | 2,255 | $144.66 | $326K | Form 4 |
| Apr 16, 2026 | William Lewis | CEO | Sale plan | 825 | $145.79 | $120K | Form 4 |
| Apr 6, 2026 | William Lewis | CEO | Sale plan | 8,478 | $163.23 | $1.4M | Form 4 |
| Apr 6, 2026 | William Lewis | CEO | Sale plan | 787 | $161.73 | $127K | Form 4 |
| Apr 6, 2026 | William Lewis | CEO | Sale plan | 1,434 | $164.01 | $235K | Form 4 |
| Apr 1, 2026 | Roger Adsett | Chief Operating Officer | Sale plan | 6,715 | $163.18 | $1.1M | Form 4 |
| Apr 1, 2026 | Roger Adsett | Chief Operating Officer | Sale plan | 62,344 | $164.95 | $10.3M | Form 4 |
| Apr 1, 2026 | Roger Adsett | Chief Operating Officer | Sale plan | 19,001 | $164.11 | $3.1M | Form 4 |
| Mar 30, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 19,638 | $150.98 | $3M | Form 4 |
| Mar 19, 2026 | William Lewis | CEO | Sale plan | 1,629 | $142.17 | $232K | Form 4 |
| Mar 19, 2026 | William Lewis | CEO | Sale plan | 4,537 | $143.42 | $651K | Form 4 |
| Mar 19, 2026 | William Lewis | CEO | Sale plan | 4,533 | $144.11 | $653K | Form 4 |
| Mar 5, 2026 | William Lewis | CEO | Sale plan | 2,128 | $147.54 | $314K | Form 4 |
| Mar 5, 2026 | William Lewis | CEO | Sale plan | 2,083 | $144.23 | $300K | Form 4 |
| Mar 5, 2026 | William Lewis | CEO | Sale plan | 2,589 | $145.27 | $376K | Form 4 |
| Mar 5, 2026 | William Lewis | CEO | Sale plan | 3,899 | $146.66 | $572K | Form 4 |
| Feb 24, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 4,852 | $153.93 | $747K | Form 4 |
| Feb 24, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 4,151 | $155.06 | $644K | Form 4 |
| Feb 24, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale plan | 15,771 | $156.53 | $2.5M | Form 4 |
| Feb 19, 2026 | William Lewis | CEO | Sale plan | 1,030 | $153.38 | $158K | Form 4 |
| Feb 19, 2026 | William Lewis | CEO | Sale plan | 3,413 | $151.12 | $516K | Form 4 |
| Feb 19, 2026 | William Lewis | CEO | Sale plan | 1,891 | $150.10 | $284K | Form 4 |
| Feb 19, 2026 | William Lewis | CEO | Sale plan | 1,988 | $149.17 | $297K | Form 4 |
| Feb 19, 2026 | William Lewis | CEO | Sale plan | 2,377 | $151.92 | $361K | Form 4 |
| Feb 9, 2026 | William Lewis | CEO | Sale plan | 1,287 | $148.83 | $192K | Form 4 |
| Feb 9, 2026 | William Lewis | CEO | Sale plan | 4,888 | $147.17 | $719K | Form 4 |
| Feb 9, 2026 | William Lewis | CEO | Sale plan | 7,221 | $148.02 | $1.1M | Form 4 |
| Feb 5, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 869 | $152.44 | $132K | Form 4 |
| Feb 3, 2026 | Roger Adsett | Chief Operating Officer | Sale | 791 | $156.17 | $124K | Form 4 |
| Feb 3, 2026 | Sara Bonstein | CFO | Sale | 748 | $156.34 | $117K | Form 4 |
| Feb 3, 2026 | William Lewis | CEO | Sale | 3,009 | $156.34 | $470K | Form 4 |
| Feb 3, 2026 | Michael Alexander Smith | Chief Legal Officer | Sale | 640 | $156.27 | $100K | Form 4 |
| Feb 3, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 795 | $155.77 | $124K | Form 4 |
| Feb 2, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 100 | $156.86 | $15.7K | Form 4 |
| Feb 2, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 3,042 | $155.46 | $473K | Form 4 |
| Feb 2, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 3,349 | $154.56 | $518K | Form 4 |
| Feb 2, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 928 | $153.16 | $142K | Form 4 |
| Feb 2, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 563 | $152.06 | $85.6K | Form 4 |
| Jan 20, 2026 | William Lewis | CEO | Sale plan | 1,006 | $156.80 | $158K | Form 4 |
| Jan 20, 2026 | William Lewis | CEO | Sale plan | 254 | $160.70 | $40.8K | Form 4 |
| Jan 20, 2026 | William Lewis | CEO | Sale plan | 1,243 | $158.37 | $197K | Form 4 |
| Jan 20, 2026 | William Lewis | CEO | Sale plan | 5,967 | $158.99 | $949K | Form 4 |
| Jan 20, 2026 | William Lewis | CEO | Sale plan | 2,229 | $159.85 | $356K | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 7,176 | $168.63 | $1.2M | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 6,996 | $169.57 | $1.2M | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 297 | $171.31 | $50.9K | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 297 | $172.36 | $51.2K | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 315 | $174.86 | $55.1K | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 3,974 | $167.73 | $667K | Form 4 |
| Jan 12, 2026 | William Lewis | CEO | Sale plan | 160 | $170.24 | $27.2K | Form 4 |
| Jan 9, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 1,887 | $186.19 | $351K | Form 4 |
| Jan 8, 2026 | Roger Adsett | Chief Operating Officer | Sale | 2,059 | $174.17 | $359K | Form 4 |
| Jan 8, 2026 | Sara Bonstein | CFO | Sale | 1,447 | $174.17 | $252K | Form 4 |
| Jan 8, 2026 | Martina M.D. Flammer | Chief Medical Officer | Sale plan | 3,251 | $174.17 | $566K | Form 4 |
Latest 100 of 152 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Roger Adsett | Chief Operating Officer | – | $48.3M | Aug 10, 2026 |
| William Lewis | Chair and CEO, Director | – | $32.8M | Jul 23, 2026 |
| Martina M.D. Flammer | Chief Medical Officer | – | $17.4M | Aug 6, 2026 |
| Orlov S Nicole Schaeffer | Chief People Strategy Officer | – | $15.3M | Jan 2, 2026 |
| Leo Lee | Director | – | $14.7M | Nov 17, 2025 |
| Michael Alexander Smith | Chief Legal Officer | – | $9M | Jun 22, 2026 |
| Melvin Md Sharoky | Director | – | $4.7M | Aug 17, 2026 |
| David R Brennan | Director | – | $3.1M | Sep 9, 2026 |
| Sara Bonstein | Chief Financial Officer | – | $2.1M | Jun 3, 2026 |
| Elizabeth M Anderson | Director | – | $1M | Nov 24, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INSM short interest
Moderate short interest. 6.4% of INSM shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 14.08M INSM shares were sold short, 6.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 3.96M shares, buying them all back would take about 3.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 14.08M | 6.42% | +4% | 3.96M | 3.6 |
| Oct 15, 2026 | 13.48M | 6.17% | -2% | 3.26M | 4.1 |
| Sep 30, 2026 | 13.80M | 6.32% | +28% | 2.12M | 6.5 |
| Sep 15, 2026 | 10.80M | 4.95% | -6% | 2.05M | 5.3 |
| Aug 31, 2026 | 11.44M | 5.24% | +5% | 1.67M | 6.9 |
| Aug 14, 2026 | 10.89M | 4.99% | -4% | 4.09M | 2.7 |
| Jul 31, 2026 | 11.35M | 5.20% | -2% | 2.21M | 5.1 |
| Jul 15, 2026 | 11.62M | 5.36% | -27% | 2.44M | 4.8 |
| Jun 30, 2026 | 16.03M | 7.40% | -14% | 5.80M | 2.8 |
| Jun 15, 2026 | 18.65M | 8.60% | -3% | 4.16M | 4.5 |
| May 29, 2026 | 19.13M | 8.83% | +9% | 3.13M | 6.1 |
| May 15, 2026 | 17.61M | 8.12% | +20% | 5.21M | 3.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded INSM
Since Nov 17, 2024, 2 members of Congress reported 1 purchase and 6 sales of INSM. The latest was a sale by Josh Gottheimer on Jun 10, 2026, reported Jul 7, 2026.
Purchases 1Sales 6
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Jul 7, 2026 | Report |
| Oct 3, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Nov 18, 2025 | Report |
| Sep 22, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Oct 10, 2025 | Report |
| Aug 8, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Sep 12, 2025 | Report |
| Jul 7, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Aug 14, 2025 | Report |
| Jun 16, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Jul 16, 2025 | Report |
| Apr 9, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | May 14, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
INSMED company events
INSMED filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 20, 2026LeadershipThe Board of Directors of Insmed Incorporated appointed Paul Hudson and Utpal Koppikar as members of the Board, effective October 19, 2026. Filing
- Oct 5, 2026LeadershipInsmed Incorporated announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 16, 2026AnnouncementShared information with investors. Filing
- May 15, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 7, 2026AnnouncementThe Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. The CEDAR study was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brensocatib in adults with moderate to… Filing
- Mar 23, 2026AnnouncementThe Company issued a press release announcing positive topline results from the ENCORE Study. Filing
- Feb 19, 2026LeadershipDavid W.J. McGirr notified the board of directors of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class II director, which will occur at the Company’s 2026 Annual Meeting of Shareholders. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
- Dec 17, 2025AnnouncementThe Company issued a press release announcing topline efficacy and safety results from the Phase 2b BiRCh study of brensocatib for patients with CRSsNP. The BiRCh study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of… Filing
- Nov 18, 2025AnnouncementOn November 18, 2025, the Company announced that the EC has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
INSMED financials
Famous investors that hold INSM
6 of the 50 well-known investors we track reported holding INSM in their latest 13F filing. The largest position is Lee Ainslie's, worth $288M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | Q3 2026 | 2.52M | $288M | 2.3% | +17% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 1.09M | $125M | 3.0% | -23% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 720,688 | $82.3M | 0.0% | -72% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 553,987 | $63.2M | 0.1% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 386,104 | $44.1M | 0.2% | -15% |
| Israel Englander · Millennium Management | Q3 2026 | 349,990 | $39.9M | 0.0% | -83% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about INSMED Inc (INSM) stock
Who owns the most INSM stock?
The largest reported owner of INSMED Inc (INSM) is FMR LLC (Fidelity), with 7.4% of the company. In total, 662 funds and institutions reported holding INSM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are INSM insiders buying or selling?
In the last 12 months, INSM insiders reported no open-market purchases and 152 sales worth $148M. The latest trade was on Sep 9, 2026. See every trade.
What is the short interest in INSM?
As of Oct 30, 2026, 14.08M INSM shares were sold short, 6.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 3.96M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.
Have members of Congress traded INSM?
Yes. 2 members of Congress reported 1 purchase and 6 sales of INSM since Nov 17, 2024. The latest was reported on Jul 7, 2026. See the trades.
Which famous investors hold INSM?
6 of the 50 well-known investors we track reported INSM in their latest 13F filing, including Lee Ainslie, Stanley Druckenmiller, Ken Griffin. The largest position is worth $288M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.